Thioredoxin in cancer-Role of histone deacetylase inhibitors Journal Article


Author: Marks, P. A.
Article Title: Thioredoxin in cancer-Role of histone deacetylase inhibitors
Abstract: Increased levels of thioredoxin (Trx) occur in a number of human cancers, which may contribute to the resistance of cancers to therapy by scavenging reactive oxygen species (ROS) which are generated by various anti-cancer agents. Many human cancers have low levels of thioredoxin-binding protein (TBP-2). TBP-2 binds to Trx and blocks its reducing activity. Histone deacetylase inhibitors (HDACi) up-regulate TBP-2 in various transformed cells, associated with a decrease in Trx levels. Up-regulation of TBP-2 and decrease of Trx may contribute to the sensitivity of many hematologic and solid tumors to anti-cancer activity of HDACi. © 2006 Elsevier Ltd. All rights reserved.
Keywords: vasculotropin; protein expression; histone deacetylase inhibitor; drug tolerability; review; doxorubicin; cancer growth; disease marker; cancer patient; neoplasms; colorectal cancer; cell proliferation; protein blood level; cell death; lung non small cell cancer; protein stability; antineoplastic activity; cancer cell culture; drug structure; drug selectivity; angiogenesis; cancer resistance; digestive system cancer; cancer inhibition; b cell lymphoma; cytokine; drug mechanism; enzyme inhibitors; colon cancer; histone deacetylase inhibitors; cell migration; reactive oxygen metabolite; cell cycle arrest; binding protein; gene control; down regulation; antioxidant activity; structure analysis; pheochromocytoma; malignant transformation; hypoxia inducible factor 1alpha; t cell leukemia; histone deacetylases; drug binding; histone deacetylase; hypoxia inducible factor 1; suberoylanilide hydroxamic acid; thioredoxin; thioredoxin-binding proteins
Journal Title: Seminars in Cancer Biology
Volume: 16
Issue: 6
ISSN: 1044-579X
Publisher: Academic Press Inc., Elsevier Science  
Date Published: 2006-12-01
Start Page: 436
End Page: 443
Language: English
DOI: 10.1016/j.semcancer.2006.09.005
PUBMED: 17095247
PROVIDER: scopus
PMCID: PMC2766865
DOI/URL:
Notes: --- - "Cited By (since 1996): 19" - "Export Date: 4 June 2012" - "CODEN: SECBE" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Paul Marks
    186 Marks
Related MSK Work